Empagliflozin Improves Atherosclerosis by Promoting Mitophagy in Endothelial Cells.
EMPA inhibits the progression of AS by activating Pink1/Parkin-mediated mitophagy, thereby improving mitochondrial function and alleviating endothelial injury and providing a novel basis for the cardiovascular protective mechanisms of EMPA.